Mylan loses Lipidil appeal, despite court finding proof of intention not needed for Swiss-style claims
Intellectual Property 2020-07-03 5:27 pm By Miklos Bolza | Sydney

Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.